Top

Published in:

01-04-2020 | Hepatocellular Carcinoma | Review

Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage

Authors: Ping Luo, Sanyun Wu, Yalan Yu, Xinliang Ming, Shuo Li, Xuelan Zuo, Jiancheng Tu

Published in: Pathology & Oncology Research | Issue 2/2020

Abstract

Hepatocellular carcinoma (HCC) is one of the most malignant cancer with high morbidity and mortality which lead to a serious burden to society. AFP (alpha-fetoprotein) is the most widely used serum biomarker to detect HCC worldwide. However, no AFP elevation have been found in many HCC and AFP analysis can’t be used to screen HCC in these cases. Currently, many studies have been carried out to find reliable biomarker in diagnosing AFP-negative HCC. Such biomarker would help the diagnosis of AFP-negative HCC, ensuring the timely initiation of treatment. In this review, we highlight the important role of biomarkers that can differentiate AFP-negative HCCs, and discuss their potential clinical applications as biomarkers for the diagnosis of AFP-negative HCC.

Gao T, Zhi J, Mu C, Gu S, Xiao J, Yang J, Wang Z, Xiang Y (2018) One-step detection for two serological biomarker species to improve the diagnostic accuracy of hepatocellular carcinoma. Talanta 178:89–93PubMedCrossRef

Cadier B, Bulsei J, Nahon P, Seror O, Laurent A, Rosa I, Layese R, Costentin C, Cagnot C, Durand-Zaleski I, Chevreul K (2017) Early detection and curative treatment of hepatocellular carcinoma: a cost-effectiveness analysis in france and in the united states. Hepatology 65:1237–1248PubMedCrossRef

Guo S, Chen W, Luo Y, Ren F, Zhong T, Rong M, Dang Y, Feng Z, Chen G (2015) Clinical implication of long non-coding rna neat1 expression in hepatocellular carcinoma patients. Int J Clin Exp Pathol 8:5395–5402PubMedPubMedCentral

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90PubMedCrossRef

Siegel RL, Miller KD, Jemal A (2016) Cancer statistics, 2016. CA Cancer J Clin 66:7–30PubMedCrossRef

Waghray A, Murali AR, Menon KN (2015) Hepatocellular carcinoma: From diagnosis to treatment. World J Hepatol 7:1020–1029PubMedPubMedCentralCrossRef

Chen KW, Ou TM, Hsu CW, Horng CT, Lee CC, Tsai YY, Tsai CC, Liou YS, Yang CC, Hsueh CW, Kuo WH (2015) Current systemic treatment of hepatocellular carcinoma: a review of the literature. World J Hepatol 7:1412–1420PubMedPubMedCentralCrossRef

Uygun Ilikhan S, Bilici M, Sahin H, Demir Akca AS, Can M, Oz II, Guven B, Buyukuysal MC, Ustundag Y (2015) Assessment of the correlation between serum prolidase and alpha-fetoprotein levels in patients with hepatocellular carcinoma. World J Gastroenterol 21:6999–7007PubMedCentralCrossRef

Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, Andersen JB, Hammerle M, Tornillo L, Heim MH, Diederichs S, Cillo C, Terracciano LM (2014) Long noncoding rna hottip/hoxa13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 59:911–923PubMedCrossRef

10.

Benson AB 3rd, Abrams TA, Ben-Josef E, Bloomston PM, Botha JF, Clary BM, Covey A, Curley SA, D'Angelica MI, Davila R, Ensminger WD, Gibbs JF, Laheru D, Malafa MP, Marrero J, Meranze SG, Mulvihill SJ, Park JO, Posey JA, Sachdev J, Salem R, Sigurdson ER, Sofocleous C, Vauthey JN, Venook AP, Goff LW, Yen Y, Zhu AX (2009) Nccn clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Cancer Netw 7:350–391CrossRef

11.

Villanueva A, Minguez B, Forner A, Reig M, Llovet JM (2010) Hepatocellular carcinoma: novel molecular approaches for diagnosis, prognosis, and therapy. Annu Rev Med 61:317–328PubMedPubMedCentralCrossRef

12.

Li J, Cheng ZJ, Liu Y, Yan ZL, Wang K, Wu D, Wan XY, Xia Y, Lau WY, Wu MC, Shen F (2015) Serum thioredoxin is a diagnostic marker for hepatocellular carcinoma. Oncotarget 6:9551–9563PubMedPubMedCentralCrossRef

13.

Johnson PJ (1999) Role of alpha-fetoprotein in the diagnosis and management of hepatocellular carcinoma. J Gastroenterol Hepatol 14(Suppl):S32–S36PubMedCrossRef

14.

Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G, Accogli E, Caraceni P, Domenicali M, De Notariis S, Roda E, Bernardi M (2001) Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of hbsag and anti-hcv status. J Hepatol 34:570–575PubMedCrossRef

15.

Han LL, Lv Y, Guo H, Ruan ZP, Nan KJ (2014) Implications of biomarkers in human hepatocellular carcinoma pathogenesis and therapy. World J Gastroenterol 20:10249–10261PubMedPubMedCentralCrossRef

16.

Chen S, Chen H, Gao S, Qiu S, Zhou H, Yu M, Tu J (2017) Differential expression of plasma microrna-125b in hepatitis b virus-related liver diseases and diagnostic potential for hepatitis b virus-induced hepatocellular carcinoma. Hepatol Res 47:312–320PubMedCrossRef

17.

Bruix J, Sherman M (2011) Management of hepatocellular carcinoma: an update. Hepatology 53:1020–1022PubMedCrossRef

18.

Oda K, Ido A, Tamai T, Matsushita M, Kumagai K, Mawatari S, Saishoji A, Kure T, Ohno K, Toyokura E, Imanaka D, Moriuchi A, Uto H, Oketani M, Hashiguchi T, Tsubouchi H (2011) Highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein is useful for early detection of hepatocellular carcinoma in patients with chronic liver disease. Oncol Rep 26:1227–1233PubMed

19.

Oeda S, Iwane S, Takasaki M, Furukawa NE, Otsuka T, Eguchi Y, Anzai K (2016) Optimal follow-up of patients with viral hepatitis improves the detection of early-stage hepatocellular carcinoma and the prognosis of survival. Intern Med 55:2749–2758PubMedPubMedCentralCrossRef

20.

Berhane S, Toyoda H, Tada T, Kumada T, Kagebayashi C, Satomura S, Schweitzer N, Vogel A, Manns MP, Benckert J, Berg T, Ebker M, Best J, Dechene A, Gerken G, Schlaak JF, Weinmann A, Worns MA, Galle P, Yeo W, Mo F, Chan SL, Reeves H, Cox T, Johnson P (2016) Role of the galad and balad-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients. Clin Gastroenterol Hepatol 14:875–886.e876PubMedCrossRef

21.

Liebman HA, Furie BC, Tong MJ, Blanchard RA, Lo KJ, Lee SD, Coleman MS, Furie B (1984) Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310:1427–1431PubMedCrossRef

22.

Furie B, Furie BC (1990) Molecular basis of vitamin k-dependent gamma-carboxylation. Blood 75:1753–1762PubMedCrossRef

23.

Seo SI, Kim HS, Kim WJ, Shin WG, Kim DJ, Kim KH, Jang MK, Lee JH, Kim JS, Kim HY, Kim DJ, Lee MS, Park CK (2015) Diagnostic value of pivka-ii and alpha-fetoprotein in hepatitis b virus-associated hepatocellular carcinoma. World J Gastroenterol 21:3928–3935PubMedPubMedCentralCrossRef

24.

Yu R, Tan Z, Xiang X, Dan Y, Deng G (2017) Effectiveness of pivka-ii in the detection of hepatocellular carcinoma based on real-world clinical data. BMC Cancer 17:608PubMedPubMedCentralCrossRef

25.

Ji J, Wang H, Li Y, Zheng L, Yin Y, Zou Z, Zhou F, Zhou W, Shen F, Gao C (2016) Diagnostic evaluation of des-gamma-carboxy prothrombin versus alpha-fetoprotein for hepatitis b virus-related hepatocellular carcinoma in China: a large-scale, multicentre study. PLoS One 11:e0153227PubMedPubMedCentralCrossRef

26.

Wang X, Zhang W, Liu Y, Gong W, Sun P, Kong X, Yang M, Wang Z (2017) Diagnostic value of prothrombin induced by the absence of vitamin k or antagonist-ii (pivka-ii) for early stage hbv related hepatocellular carcinoma. Infect Agent Cancer 12:47PubMedPubMedCentralCrossRef

27.

Oka H, Saito A, Ito K, Kumada T, Satomura S, Kasugai H, Osaki Y, Seki T, Kudo M, Tanaka M (2001) Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 16:1378–1383PubMedCrossRef

28.

Kumada T, Toyoda H, Kiriyama S, Tanikawa M, Hisanaga Y, Kanamori A, Tada T, Tanaka J, Yoshizawa H (2011) Predictive value of tumor markers for hepatocarcinogenesis in patients with hepatitis c virus. J Gastroenterol 46:536–544PubMedCrossRef

29.

Toyoda H, Kumada T, Tada T, Kaneoka Y, Maeda A, Kanke F, Satomura S (2011) Clinical utility of highly sensitive lens culinaris agglutinin-reactive alpha-fetoprotein in hepatocellular carcinoma patients with alpha-fetoprotein <20 ng/ml. Cancer Sci 102:1025–1031PubMedCrossRef

30.

Best J, Bilgi H, Heider D, Schotten C, Manka P, Bedreli S, Gorray M, Ertle J, van Grunsven LA, Dechene A (2016) The galad scoring algorithm based on afp, afp-l3, and dcp significantly improves detection of bclc early stage hepatocellular carcinoma. Z Gastroenterol 54:1296–1305PubMedCrossRef

31.

Zhang Z, Zhang Y, Wang Y, Xu L, Xu W (2016) Alpha-fetoprotein-l3 and golgi protein 73 may serve as candidate biomarkers for diagnosing alpha-fetoprotein-negative hepatocellular carcinoma. OncoTargets Ther 9:123–129

32.

Khraiwesh B, Zhu JK, Zhu J (1819) Role of mirnas and sirnas in biotic and abiotic stress responses of plants. Biochim Biophys Acta 2012:137–148

33.

Shi M, Jiang Y, Yang L, Yan S, Wang YG, Lu XJ (2018) Decreased levels of serum exosomal mir-638 predict poor prognosis in hepatocellular carcinoma. J Cell Biochem 119:4711–4716PubMedCrossRef

34.

Liu HN, Wu H, Chen YJ, Tseng YJ, Bilegsaikhan E, Dong L, Shen XZ, Liu TT (2017) Serum microrna signatures and metabolomics have high diagnostic value in hepatocellular carcinoma. Vet Comp Oncol 8:108810–108824

35.

Lai YC, Ushio N, Rahman MM, Katanoda Y, Ogihara K, Naya Y, Moriyama A, Iwanaga T, Saitoh Y, Sogawa T, Sunaga T, Momoi Y, Izumi H, Miyoshi N, Endo Y, Fujiki M, Kawaguchi H, Miura N (2018) Aberrant expression of microRNAs and the mir-1/met pathway in canine hepatocellular carcinoma. Vet Comp Oncol 16:288–296PubMedCrossRef

36.

Lyra-Gonzalez I, Flores-Fong LE, Gonzalez-Garcia I, Medina-Preciado D, Armendariz-Borunda J (2015) Micrornas dysregulation in hepatocellular carcinoma: insights in genomic medicine. World J Hepatol 7:1530–1540PubMedPubMedCentralCrossRef

37.

Wu XM, Xi ZF, Liao P, Huang HD, Huang XY, Wang C, Ma Y, Xia Q, Yao JG, Long XD (2017) Diagnostic and prognostic potential of serum microrna-4651 for patients with hepatocellular carcinoma related to aflatoxin b1. Oncotarget 8:81235–81249PubMedPubMedCentralCrossRef

38.

Guo X, Lv X, Lv X, Ma Y, Chen L, Chen Y (2017) Circulating mir-21 serves as a serum biomarker for hepatocellular carcinoma and correlated with distant metastasis. Oncotarget 8:44050–44058PubMedPubMedCentralCrossRef

39.

Zuo D, Chen L, Liu X, Wang X, Xi Q, Luo Y, Zhang N, Guo H (2016) Combination of mir-125b and mir-27a enhances sensitivity and specificity of afp-based diagnosis of hepatocellular carcinoma. Tumour Biol 37:6539–6549PubMedCrossRef

40.

Lin XJ, Chong Y, Guo ZW, Xie C, Yang XJ, Zhang Q, Li SP, Xiong Y, Yuan Y, Min J, Jia WH, Jie Y, Chen MS, Chen MX, Fang JH, Zeng C, Zhang Y, Guo RP, Wu Y, Lin G, Zheng L, Zhuang SM (2015) A serum microrna classifier for early detection of hepatocellular carcinoma: a multicentre, retrospective, longitudinal biomarker identification study with a nested case-control study. Lancet Oncol 16:804–815PubMedCrossRef

41.

Wang X, Song X, Zhuo W, Fu Y, Shi H, Liang Y, Tong M, Chang G, Luo Y (2009) The regulatory mechanism of hsp90alpha secretion and its function in tumor malignancy. Proc Natl Acad Sci U S A 106:21288–21293PubMedPubMedCentralCrossRef

42.

Fu Y, Xu X, Huang D, Cui D, Liu L, Liu J, He Z, Liu J, Zheng S, Luo Y (2017) Plasma heat shock protein 90alpha as a biomarker for the diagnosis of liver cancer: an official, large-scale, and multicenter clinical trial. EBioMedicine 24:56–63PubMedPubMedCentralCrossRef

43.

Fan Y, Li Y, Chen Y, Zhao YJ, Liu LW, Li J, Wang SL, Alolga RN, Yin Y, Wang XM, Zhao DS, Shen JH, Meng FQ, Zhou X, Xu H, He GP, Lai MD, Li P, Zhu W, Qi LW (2016) Comprehensive metabolomic characterization of coronary artery diseases. J Am Coll Cardiol 68:1281–1293PubMedCrossRef

44.

Luo P, Yin P, Hua R, Tan Y, Li Z, Qiu G, Yin Z, Xie X, Wang X, Chen W, Zhou L, Wang X, Li Y, Chen H, Gao L, Lu X, Wu T, Wang H, Niu J, Xu G (2017) A large-scale, multi-center serum metabolite biomarkers identification study for the early detection of hepatocellular carcinoma. Hepatology https://doi.org/10.1002/hep.29561 PubMedCrossRef

45.

Xu H, Dong X, Chen Y, Wang X (2017) Serum exosomal hnRNPH1 mRNA as a novel marker for hepatocellular carcinoma. Clin Chem Lab Med 56:479–484CrossRef

46.

Caviglia GP, Abate ML, Petrini E, Gaia S, Rizzetto M, Smedile A (2016) Highly sensitive alpha-fetoprotein, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection. Hepatol Res 46:E130–E135PubMedCrossRef

47.

Song P, Feng X, Inagaki Y, Song T, Zhang K, Wang Z, Zheng S, Ma K, Li Q, Kong D, Wu Q, Zhang T, Zhao X, Hasegawa K, Sugawara Y, Kokudo N, Tang W (2014) Clinical utility of simultaneous measurement of alpha-fetoprotein and des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinoma in China: a multi-center case-controlled study of 1,153 subjects. Biosci Trends 8:266–273PubMedCrossRef

48.

Tang J, Jiang R, Deng L, Zhang X, Wang K, Sun B (2015) Circulation long non-coding rnas act as biomarkers for predicting tumorigenesis and metastasis in hepatocellular carcinoma. Oncotarget 6:4505–4515PubMedPubMedCentralCrossRef

Title: Current Status and Perspective Biomarkers in AFP Negative HCC: Towards Screening for and Diagnosing Hepatocellular Carcinoma at an Earlier Stage
Authors: Ping Luo
Sanyun Wu
Yalan Yu
Xinliang Ming
Shuo Li
Xuelan Zuo
Jiancheng Tu
Publication date: 01-04-2020
Publisher: Springer Netherlands
Keywords: Hepatocellular Carcinoma
Hepatocellular Carcinoma
Biomarkers
Published in: Pathology & Oncology Research / Issue 2/2020
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00585-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2020

Peptidyl Arginine Deiminase, Type II (PADI2) Is Involved in Urothelial Bladder Cancer

Total Serum Cholesterol and Pancreatic Cancer Risk: What Is the Link?

Comprehensive Data of P53 R282 Gene Mutation with Human Papillomaviruses (HPV)-Associated Oral Squamous Cell Carcinoma (OSCC)

Immune Checkpoint Inhibitor Therapy in HIV-Positive Patients with Advanced-Stage Cancer: a Golden Card to Be Played?

Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma

Solid-pseudopapillary Neoplasms of the Pancreas is still an Enigma: a Clinicopathological Review

Keynote webinar | Spotlight on antibody–drug conjugates in cancer